79 completed, 75 recruiting, 43 not yet recruiting, 30 active not recruiting. 69 Phase 2, 55 Phase 3, 40 Phase 4, 35 Phase 1, 15 Not applicable.
Follow Tirzepatide: new trials by email Literature Review of Tirzepatide trials Research Report on Tirzepatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tirzepatide for the Treatment of Cannabis Use Disorder Tirzepatide, Placebo - Cannabis Use Disorder | Phase 2 | Not yet recruiting | Brigham and Women's Hospital | 6 | 2027-03-01 | 2026-10-09 |
| Effects of Tirzepatide on Gut Microbiota and Gastrointestinal Function After Drug Withdrawal in Obese Patients Tirzepatide - Obesity / Overweight | Not yet recruiting | Nanjing First Hospital, Nanjing Medical University | 80 | 2027-02-01 | 2026-10-15 | |
| Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer Tirzepatide - Endometrial Cancer, Endometrial Intraepithelial Neoplasia | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 40 | 2027-01-01 | 2026-09-28 |
| Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Tirzepatide, Placebo - Obesity | Phase 3 | Not yet recruiting | Universidade do Porto | 70 | 2027-01-01 | 2026-09-18 |
| Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity Tirzepatide - Type 1 Diabetes Mellitus, Overweight and Obesity | Phase 2 | Not yet recruiting | Royal North Shore Hospital | 40 | 2026-12-01 | 2025-07-29 |
| A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes eloralintide and tirzepatide, Eloralintide, Tirzepatide - Obesity | Phase 3 | Not yet recruiting | Eli Lilly and Company | 2115 | 2026-12-01 | 2026-10-19 |
| A Clinical Study to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participants With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose-Lowering Medications Enicepatide, Tirzepatide - Type 2 Diabetes Mellitus | Phase 3 | Not yet recruiting | Hoffmann-La Roche | 948 | 2026-12-01 | 2026-10-22 |
| Trial of Tirzepatide for the Treatment of Cannabis Use Disorder Tirzepatide, Placebo - Cannabis Use Disorder | Phase 2 | Not yet recruiting | National Institute on Drug Abuse (NIDA) | 100 | 2026-11-15 | 2026-09-21 |
| A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3) - T2DM (Type 2 Diabetes Mellitus) | Phase 2 | Not yet recruiting | CSPC Ouyi Pharmaceutical Co., Ltd. | 240 | 2026-11-06 | 2026-09-01 |
| Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM) Tirzepatide, Life Style Modification - Obesity | Not yet recruiting | Dr. Md. Alimur Reza | 364 | 2026-11-01 | 2026-10-07 | |
| Tirzepatide and Levonorgestrel IUD Therapy for EIN and Early-Stage Endometrial Cancer Tirzepatide - Grade 1 Endometrial Endometrioid Carcinoma, Endometrial Intraepithelial Neoplasia | Early Phase 1 | Not yet recruiting | Milton S. Hershey Medical Center | 15 | 2026-11-01 | 2026-09-10 |
| A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer Medical Device Usage and Evaluation, Tirzepatide - Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 55 | 2026-11-01 | 2026-08-26 |
| A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes eloralintide and tirzepatide, Tirzepatide - Obesity, Overweight | Phase 3 | Not yet recruiting | Eli Lilly and Company | 1000 | 2026-11-01 | 2026-10-19 |
| Metabolic Effects of Switching From Injectable Semaglutide to Tirzepatide Tirzepatide - Obesity, Type 2 Diabetes (T2D) | Active not recruiting | LMC Diabetes & Endocrinology Ltd. | 650 | 2026-10-15 | 2026-10-22 | |
| PROACT AYA: Preventing Overweight/Obesity-Associated Cardiotoxicity With Tirzepatide In Adolescent And Young Adult Cancer Survivors - A Phase 2 Single-Arm, Single-Center Feasibility Study Tirzepatide - Sarcoma,Soft Tissue | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-10-14 | 2026-10-20 |
| A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication Tirzepatide, Zenagamtide - Overweight, Obesity | Phase 1 | Recruiting | Novo Nordisk A/S | 60 | 2026-10-08 | 2026-10-16 |
| Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib Tirzepatide - Lung Cancer | Phase 1 | Not yet recruiting | University of Chicago | 30 | 2026-10-01 | 2026-08-24 |
| Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder Tirzepatide, Placebo (saline) - Methamphetamine Use Disorder | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 228 | 2026-10-01 | 2026-09-23 |
| Tirzepatide Versus Positive Airway Pressure for the Treatment of Obstructive Sleep Apnoea: A Randomised Comparative Effectiveness Trial Continuous Positive Airway Pressure, Tirzepatide - Sleep Apnoea, Obesity & Overweight | Phase 2 / Phase 3 | Not yet recruiting | Woolcock Institute of Medical Research | 256 | 2026-10-01 | 2026-09-29 |
| A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity Semaglutide, Berobenatide, Tirzepatide - Obesity, Overweight and/or Obesity | Phase 3 | Recruiting | Pfizer | 660 | 2026-09-30 | 2026-10-15 |
Showing 20 of 238. Sign in to see all of them.
Obesity (143) · Overweight (71) · Diabetes Mellitus, Type 2 (61) · Weight Loss (14) · Diabetes Mellitus (13) · Nutrition Disorders (8) · Diabetes Mellitus, Type 1 (7) · Metabolic Diseases (7) · Alcoholism (6) · Atrial Fibrillation (5) · Endocrine System Diseases (5) · Glucose Metabolism Disorders (5) · Insulin Resistance (5) · Metabolic Syndrome (5) · Arthritis, Psoriatic (4)
Eli Lilly and Company (79) · Brigham and Women's Hospital (10) · Novo Nordisk A/S (5) · The Cleveland Clinic (4) · Mayo Clinic (3) · Nanjing First Hospital, Nanjing Medical University (3) · Shahid Beheshti University of Medical Sciences (3) · University of Texas Southwestern Medical Center (3) · Cambridge University Hospitals NHS Foundation Trust (2) · Dasman Diabetes Institute (2) · Hoffmann-La Roche (2) · Johns Hopkins University (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (2)
United States (149) · China (28) · Puerto Rico (28) · Argentina (24) · Mexico (22) · Canada (20) · Japan (19) · Australia (18) · Brazil (18) · Germany (18) · Spain (18) · Taiwan (18) · Israel (15) · Poland (15) · United Kingdom (15)
Shirley Wang, PhD, ScM (6) · Jason M Samuels, MD (2) · Manish Jha, M.B.B.S. (2) · Ahmad Haidar, PhD (1) · Alaa Sada, MD (1) · Alexa N Bramall, MD (1) · Ali Aminian (1) · Ali Aminian, MD (1) · Amy Attaway, MD (1) · Ana Checa-Ros, MD, PhD (1)
PMID 35210595, PMID 37526908, PMID 37668888, PMID 39531161, PMID 40512543, PMID 40717199, PMID 40886075, PMID 41187013, PMID 41537305, PMID 41885866, PMID 34170647, PMID 35658024, PMID 37000390, PMID 39536238, PMID 39566869, PMID 39800653, PMID 40711720, PMID 40903131, PMID 41207920, PMID 41406444, PMID 41640675, PMID 41903163, PMID 41961454, PMID 42348366, PMID 16415884, PMID 17434869, PMID 25471927, PMID 25671797, PMID 25673413, PMID 26898852, PMID 27296974, PMID 28052979, PMID 28701474, PMID 29129157, PMID 29364767, PMID 29402504, PMID 30104762, PMID 30124842, PMID 30170852, PMID 30293770, PMID 30473097, PMID 30878104, PMID 31662037, PMID 32154773, PMID 32291277, PMID 33567185, PMID 33778934, PMID 34186022, PMID 34370970, PMID 34608929
2023 (7), 2019 (5), 2018 (4), 2025 (2), 1OT2CA297680-01 (1), 2016 (1), KL2TR002385 (1), P30CA016672 (1), P30CA033572 (1), P50MD017344 (1), R01DK097554 (1), R01DK138915 (1), R21AA031892 (1), U01CA281026 (1), U01DA064384 (1)